Quality of life 1 year after uterine artery embolization vs hysterectomy for symptomatic adenomyosis ( QUESTA study)
Acta Obstetricia et Gynecologica Scandinavica · 2025-08 · 104 (8) · 1558-1574
DOI: 10.1111/aogs.15165 ↗At a glance
Randomisierte kontrollierte Studie in Acta Obstetricia et Gynecologica Scandinavica, published online on 2025-05-26. Written by Lisa M Trommelen and 40 co-authors. Institution: Department of Obstetrics and Gynecology, Amsterdam UMC, Location VUMC and AMC, Amsterdam, The Netherlands. Major MEDLINE topics: Adenomyosis, Quality of Life, Hysterectomy, Uterine Artery Embolization. Cited 7 times so far (Crossref); 28 references. The full text is freely available (open access, CC BY-NC-ND 4.0). Funded by: Boston Scientific Corporation, Merit Medical Systems.
Abstract (original language)
Introduction
Uterine artery embolization (UAE) is a less‐invasive alternative for hysterectomy in therapy‐resistant symptomatic adenomyosis. Comparative data are lacking. Our objective is to evaluate the non‐inferiority of UAE compared with hysterectomy in improving health‐related quality of life (HRQOL) for symptomatic adenomyosis, 1 year post‐treatment. Material and Methods This multicenter randomized controlled trial was converted into a prospective cohort study. It was prospectively registered at 27‐07‐2015 (NL‐OMON55436, https://onderzoekmetmensen.nl/en/trial/55436 ). From November 2015 to March 2022 participants with symptomatic adenomyosis eligible for hysterectomy were included and offered UAE as an alternative treatment. Primary endpoint was difference in 1‐year HRQOL scores between UAE and hysterectomy, using WHO‐QOL‐Bref and SF‐12. Non‐inferiority margin was set at five points. Secondary endpoints: WHO‐QOL‐100 facets “Pain and Discomfort” and “Sexual Activity”, adenomyosis‐related symptoms, and satisfaction. Multivariable linear mixed models were used. All outcomes were analyzed in the per‐protocol population, and repeated in the intention‐to‐treat population.
Results
Of 101 participants, 51 chose hysterectomy and 50 UAE. Both treatment groups were comparable at baseline, except for employment status, dysmenorrhea score, uterine volume, hemoglobin and CA125 (all adjusted for). Both treatments led to a significant increase in all HRQOL scores after 1 year. The effect differences between UAE and hysterectomy on all HRQOL domains in the per‐protocol population were: SF‐12 physical β −4.20, (95% CI −9.53 to 1.12), SF‐12 mental β −4.95 (95% CI −10.83 to 0.94); WHO‐QOL‐Bref physical β −7.42 (95% CI −18.51 to 3.68), psychological β −4.28 (95% CI −13.30 to 4.74), social relations β −2.23 (95% CI −13.09 to 8.63) and environment β 0.35 (95% CI −8.39 to 9.09). Non‐inferiority of UAE was not demonstrated within the predefined margin. Both hysterectomy and UAE improved “Pain and Discomfort” and “Sexual Activity”, with greater effect on pain after hysterectomy ( β 17.17, 95% CI 4.94 to 29.41, p = 0.007). More participants were satisfied after hysterectomy (95%) than after UAE (73%).
Conclusions
Both UAE and hysterectomy significantly increased HRQOL for symptomatic adenomyosis. Neither non‐inferiority nor inferiority of UAE could be established. One‐year HRQOL scores were comparable; some secondary outcomes were in favor of hysterectomy. UAE is a valid less‐invasive alternative to hysterectomy, with preservation of the uterus. Hysterectomy remains the treatment of choice for patients seeking a definite solution.
Subjects
MeSH terms (MEDLINE)
Author keywords
Authors and institutions
- Department of Obstetrics and Gynecology, Amsterdam UMC, Location VUMC and AMC, Amsterdam, The Netherlands.
- Amsterdam Reproduction and Development (AR&D), Research Institute, Amsterdam, The Netherlands.
- Department of Obstetrics and Gynecology, Elisabeth Tweesteden Ziekenhuis, Tilburg, The Netherlands.
- Department of Obstetrics and Gynecology, Amphia Ziekenhuis, Breda, The Netherlands.
- Department of Obstetrics and Gynecology, Maxima Medical Center, Eindhoven, The Netherlands.
- Department of Obstetrics and Gynecology, OLVG, Amsterdam, The Netherlands.
ORCID profiles: Lisa M Trommelen
Funding
- Boston Scientific Corporation
- Merit Medical Systems
Cite
APA
Trommelen, L. M., Semmler, A., de Bruijn, A. M., Harmsen, M., Smink, M., Janssen, P. F., van Rooij, I., van Bavel, J., Geomini, P., Maas, J. W. M., Radder, C. M., van Kesteren, P., Kwee, J., Bakkum, E., de Lange, M., de Leeuw, R. A., Groenman, F., Mijatovic, V., Timmermans, A., …, & Hehenkamp, W. J. K. (2025). Quality of life 1 year after uterine artery embolization vs hysterectomy for symptomatic adenomyosis ( QUESTA study). Acta Obstetricia et Gynecologica Scandinavica, 104(8), 1558-1574. https://doi.org/10.1111/aogs.15165
Vancouver
Trommelen LM, Semmler A, de Bruijn AM, Harmsen M, Smink M, Janssen PF, et al. Quality of life 1 year after uterine artery embolization vs hysterectomy for symptomatic adenomyosis ( QUESTA study). Acta Obstetricia et Gynecologica Scandinavica. 2025;104(8):1558-1574. doi:10.1111/aogs.15165
BibTeX
@article{Trommelen2025,
author = {Trommelen, Lisa M and Semmler, Annika and de Bruijn, Annefleur M and Harmsen, Marissa and Smink, Marieke and Janssen, Petra F and van Rooij, Ilse and van Bavel, Jeroen and Geomini, Peggy and Maas, Jacques W M and Radder, Celine M and van Kesteren, Paul and Kwee, Janet and Bakkum, Erica and de Lange, Marleen and de Leeuw, Robert A and Groenman, Freek and Mijatovic, Velja and Timmermans, Anne and Lely, Rutger and Lamers, Armand and Vos, Douwe and van Hoecke, Gretel and Elgersma, Otto and van Vliet, Huib A A M and Yo, Lonneke S F and Twijnstra, Andries R H and Jansen, Frank W and van Rijswijk, Catharina S P and Kruimer, Han and Tseng, Carroll M E S N and Coppus, Sjors and Arntz, Mark and Wust, Aloys F J and Blomjous, Joost G A M and van Boven, Laurens and Venmans, Alexander and Twisk, Jos W R and Huirne, Judith A F and Lohle, Paul N M and Hehenkamp, Wouter J K},
title = {Quality of life 1 year after uterine artery embolization vs hysterectomy for symptomatic adenomyosis ( QUESTA study)},
journal = {Acta Obstetricia et Gynecologica Scandinavica},
year = {2025},
volume = {104},
number = {8},
pages = {1558--1574},
doi = {10.1111/aogs.15165}
}
EUVIMED